Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
69 hedge funds and large institutions have $114M invested in Odonate Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 27 reducing their positions, and 26 closing their positions.
141% more call options, than puts
Call options by funds: $685K | Put options by funds: $284K
3% more capital invested
Capital invested by funds: $111M → $114M (+$3.35M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 83 → 69 (-14)
30% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 27
54% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.72M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.85M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.23M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$1.17M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.04M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.13M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.08M |
| 4 |
Two Sigma Investments
New York
|
-$889K |
| 5 |
State Street
Boston,
Massachusetts
|
-$879K |
ODT Hedge Fund Activity: Q2 2021 in Review
69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q2 2021, worth a combined $114M — up 3% from $111M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ODT and 12 opened new positions — a net loss of 14 holders — while 27 trimmed existing stakes and 19 added.
The largest buyer was Morgan Stanley, adding an estimated $3.72M. The largest seller was BlackRock, cutting an estimated $3.04M.
- 69 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q2 2021, down from 83 in Q1 2021.
- Funds reported $114M of Odonate Therapeutics, Inc. Common Stock stock for Q2 2021, up 3% quarter-over-quarter.
- 12 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q2 2021 and 26 closed out, a net change of -14 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q2 2021 was Morgan Stanley, an estimated $3.72M added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q2 2021 was BlackRock, an estimated $3.04M sold.
Based on aggregated 13F filings for Q2 2021.